Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action

Introduction: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanism...

Full description

Bibliographic Details
Main Authors: Madison N. Irwin, PharmD, Amy VandenBerg, PharmD, BCPP
Format: Article
Language:English
Published: American Association of Psychiatric Pharmacists 2021-05-01
Series:Mental Health Clinician
Subjects:
Online Access:https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.200
_version_ 1797383402929782784
author Madison N. Irwin, PharmD
Amy VandenBerg, PharmD, BCPP
author_facet Madison N. Irwin, PharmD
Amy VandenBerg, PharmD, BCPP
author_sort Madison N. Irwin, PharmD
collection DOAJ
description Introduction: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanisms underlying the efficacy of ketamine are not well understood and many other mechanisms outside of NMDAR antagonism have been postulated based on preclinical data. This focused review aims to present a summary of the proposed mechanisms of action by which ketamine functions in depressive disorders supported by preclinical data and clinical studies in humans. Methods: A literature search was completed using the PubMed and Google Scholar databases. Results were limited to clinical trials and case studies in humans that were published in English. The findings were used to compile this article. Results: The antidepressant effects associated with ketamine are mediated via a complex interplay of mechanisms; key steps include NMDAR blockade on ?-aminobutyric acid interneurons, glutamate surge, and subsequent activation and upregulation of ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. Discussion: Coadministration of ketamine for MDD with other psychotropic agents, for example benzodiazepines, may attenuate antidepressant effects. Limited evidence exists for these effects and should be evaluated on a case-by-case basis.
first_indexed 2024-03-08T21:20:27Z
format Article
id doaj.art-8b2c9f5bee5145a1ba2e5730da4427dc
institution Directory Open Access Journal
issn 2168-9709
language English
last_indexed 2024-03-08T21:20:27Z
publishDate 2021-05-01
publisher American Association of Psychiatric Pharmacists
record_format Article
series Mental Health Clinician
spelling doaj.art-8b2c9f5bee5145a1ba2e5730da4427dc2023-12-21T11:42:11ZengAmerican Association of Psychiatric PharmacistsMental Health Clinician2168-97092021-05-0111320021010.9740/mhc.2021.05.200i2168-9709-11-3-200Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of actionMadison N. Irwin, PharmD0https://orcid.org/0000-0003-3769-7035Amy VandenBerg, PharmD, BCPP1https://orcid.org/0000-0002-2294-26941 PGY-2 Pain Management and Palliative Care Pharmacy Resident, Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan2 Clinical Pharmacist Specialist in Psychology and Neurology, Department of Pharmacy, Michigan Medicine, Ann Arbor, MichiganIntroduction: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanisms underlying the efficacy of ketamine are not well understood and many other mechanisms outside of NMDAR antagonism have been postulated based on preclinical data. This focused review aims to present a summary of the proposed mechanisms of action by which ketamine functions in depressive disorders supported by preclinical data and clinical studies in humans. Methods: A literature search was completed using the PubMed and Google Scholar databases. Results were limited to clinical trials and case studies in humans that were published in English. The findings were used to compile this article. Results: The antidepressant effects associated with ketamine are mediated via a complex interplay of mechanisms; key steps include NMDAR blockade on ?-aminobutyric acid interneurons, glutamate surge, and subsequent activation and upregulation of ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. Discussion: Coadministration of ketamine for MDD with other psychotropic agents, for example benzodiazepines, may attenuate antidepressant effects. Limited evidence exists for these effects and should be evaluated on a case-by-case basis.https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.200ketaminemajor depressive disordermddmechanismdrug-drug interaction
spellingShingle Madison N. Irwin, PharmD
Amy VandenBerg, PharmD, BCPP
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
Mental Health Clinician
ketamine
major depressive disorder
mdd
mechanism
drug-drug interaction
title Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
title_full Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
title_fullStr Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
title_full_unstemmed Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
title_short Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
title_sort retracing our steps to understand ketamine in depression a focused review of hypothesized mechanisms of action
topic ketamine
major depressive disorder
mdd
mechanism
drug-drug interaction
url https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.200
work_keys_str_mv AT madisonnirwinpharmd retracingourstepstounderstandketamineindepressionafocusedreviewofhypothesizedmechanismsofaction
AT amyvandenbergpharmdbcpp retracingourstepstounderstandketamineindepressionafocusedreviewofhypothesizedmechanismsofaction